Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001999371-24-009003
Filing Date
2024-07-24
Accepted
2024-07-24 17:14:39
Documents
13
Period of Report
2024-05-21
Items
Item 2.06: Material Impairments
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM 8-K tnxp-8ka_072424.htm   iXBRL 8-K/A 25682
  Complete submission text file 0001999371-24-009003.txt   200334

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tnxp-20240521.xsd EX-101.SCH 3024
3 XBRL LABEL FILE tnxp-20240521_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tnxp-20240521_pre.xml EX-101.PRE 22365
15 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8ka_072424_htm.xml XML 3655
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36019 | Film No.: 241138993
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)